Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meticrane is a small molecule diuretic of the sulphonamide class with thiazide-like activity. It acts by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubule of the nephron in the kidney. This leads to increased excretion of sodium and water, resulting in a reduction in blood volume and lower blood pressure. It has been marketed primarily in Japan under brand names such as Arresten for the treatment of essential hypertension[1][2][4][5][9]. Its mechanism is similar to that of thiazide diuretics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meticrane.